Lycia Therapeutics Launches U.S. IPO For Food Allergy, Graves' Disease Pipeline

🇺🇸 Seeking Alpha (US) —

AI Summary

Lycia Therapeutics has launched a U.S. initial public offering to support its pipeline targeting food allergies and Graves’ disease. The headline does not specify offering size, pricing, or other transaction terms.

Markets Deals Health Lycia Therapeutics IPO biotechnology food allergy Graves' disease drug pipeline

Read original source →